Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
CNY 5.15
(0.0%)
CNY 5.15
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 28.26 Million CNY | -7.42% |
| 2022 | 30.53 Million CNY | 13.67% |
| 2021 | 26.86 Million CNY | 129.83% |
| 2020 | 11.68 Million CNY | 4939.34% |
| 2019 | 231.93 Thousand CNY | 65.55% |
| 2018 | 140.09 Thousand CNY | 14009399.97% |
| 2017 | 1.00 CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| 2015 | - CNY | -100.0% |
| 2014 | 311.02 Thousand CNY | -96.89% |
| 2013 | 10 Million CNY | 3505.97% |
| 2012 | 277.31 Thousand CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 69.1 Million CNY | 86.7% |
| 2024 Q3 | 52.78 Million CNY | 0.01% |
| 2024 Q1 | 28.26 Million CNY | 0.0% |
| 2023 Q3 | 44.83 Million CNY | 19.96% |
| 2023 Q4 | 28.26 Million CNY | -36.95% |
| 2023 FY | 28.26 Million CNY | -7.42% |
| 2023 Q1 | 28.3 Million CNY | -7.29% |
| 2023 Q2 | 37.37 Million CNY | 32.02% |
| 2022 Q4 | 30.53 Million CNY | 32.36% |
| 2022 FY | 30.53 Million CNY | 13.67% |
| 2022 Q1 | 25.45 Million CNY | -5.23% |
| 2022 Q2 | 35.95 Million CNY | 41.25% |
| 2022 Q3 | 23.06 Million CNY | -35.84% |
| 2021 Q3 | 11.35 Million CNY | 91.45% |
| 2021 Q2 | 5.93 Million CNY | 3800.76% |
| 2021 Q4 | 26.86 Million CNY | 136.51% |
| 2021 FY | 26.86 Million CNY | 129.83% |
| 2021 Q1 | 152.08 Thousand CNY | -8.99% |
| 2020 Q1 | 212.94 Thousand CNY | -8.19% |
| 2020 Q4 | 167.1 Thousand CNY | -14.5% |
| 2020 FY | 11.68 Million CNY | 4939.34% |
| 2020 Q2 | 210.98 Thousand CNY | -0.92% |
| 2020 Q3 | 195.44 Thousand CNY | -7.36% |
| 2019 Q1 | 133.37 Thousand CNY | -4.8% |
| 2019 FY | 231.93 Thousand CNY | 65.55% |
| 2019 Q3 | 215.15 Thousand CNY | -4.4% |
| 2019 Q4 | 231.93 Thousand CNY | 7.8% |
| 2019 Q2 | 225.05 Thousand CNY | 68.74% |
| 2018 FY | 140.09 Thousand CNY | 14009399.97% |
| 2018 Q4 | 140.09 Thousand CNY | 0.0% |
| 2018 Q3 | - CNY | 100.0% |
| 2018 Q2 | - CNY | 0.0% |
| 2018 Q1 | - CNY | -100.0% |
| 2017 Q3 | - CNY | 0.0% |
| 2017 Q4 | 1.00 CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |
| 2017 Q1 | - CNY | 0.0% |
| 2017 Q2 | - CNY | 0.0% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 Q2 | - CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2015 FY | - CNY | -100.0% |
| 2014 FY | 311.02 Thousand CNY | -96.89% |
| 2013 FY | 10 Million CNY | 3505.97% |
| 2012 FY | 277.31 Thousand CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 2.33 Billion CNY | 98.787% |
| Hangzhou Tigermed Consulting Co., Ltd. | 434.22 Million CNY | 93.49% |
| Dirui Industrial Co.,Ltd. | 3.66 Million CNY | -670.887% |
| Beijing Strong Biotechnologies, Inc. | 1.13 Billion CNY | 97.502% |
| Medicalsystem Biotechnology Co., Ltd. | 23.59 Million CNY | -19.802% |
| Maccura Biotechnology Co.Ltd | 175.47 Million CNY | 83.891% |
| Guangzhou Wondfo Biotech Co.,Ltd | 580.52 Million CNY | 95.131% |
| BGI Genomics Co., Ltd. | 283.42 Million CNY | 90.026% |
| Amoy Diagnostics Co., Ltd. | 44.4 Million CNY | 36.332% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 166.83 Million CNY | 83.056% |